{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:29:13Z","timestamp":1792211353690,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Intrahepatic cholangiocarcinoma (iCCA) represents a biologically heterogeneous subgroup of biliary tract cancer (BTC) with a 5-year survival below 20%. Delayed diagnosis, intrinsic aggressiveness, and extensive intertumoral and intratumoral heterogeneity at the clinical, histopathological, and genomic level all contribute to this dismal outcome. Increasingly, treatment decisions in advanced iCCA depend on the identification of actionable molecular alterations, including FGFR2 fusions or rearrangements, IDH1 mutations, HER2 amplifications, NTRK fusions, and microsatellite instability (MSI-high) and\/or mismatch repair deficiency (dMMR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of the current literature was conducted, focusing on (i) what molecular alterations are clinically relevant today, (ii) when molecular profiling should be performed, and (iii) how testing should be technically implemented in routine clinical practice. Results iCCA, particularly the small-duct subtype, harbors a high prevalence of therapeutically actionable molecular alterations, in contrast to extrahepatic cholangiocarcinoma and gallbladder carcinoma. Early and comprehensive molecular profiling enables access to approved targeted therapies, molecularly stratified second-line treatments, and clinical trials. Combined DNA- and RNA-based next-generation sequencing, complemented by immunohistochemistry and in situ hybridization, provides the most reliable diagnostic framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Molecular testing has become an essential component of modern iCCA management. Broad, early, and technically integrated molecular profiling\u2014ideally performed at initial diagnosis and interpreted in an interdisciplinary (molecular) tumor board\u2014is critical to fully realize the potential of precision oncology in BTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01397-y","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:10:41Z","timestamp":1768446641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?"],"prefix":"10.1007","volume":"57","author":[{"given":"Maryam","family":"Barsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine-Pashupati","family":"Dopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Maria","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"1397_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380. https:\/\/doi.org\/10.1038\/nrgastro.2016.51.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1397_CR2","unstructured":"Barsch M, Bengsch B. Das cholangiozellul\u00e4re Karzinom: State of the Art 2024. 1\/2024 | Falk Gastro-Kolleg."},{"key":"1397_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1397_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2 -rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"key":"1397_CR6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807. https:\/\/doi.org\/10.1016\/S1470-2045(20)30157-1.","journal-title":"Lancet Oncol"},{"key":"1397_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh D-Y, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(23)00242-5.","journal-title":"Lancet Oncol"},{"key":"1397_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study. JCO. 2020;38:1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"JCO"},{"key":"1397_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med. 2018;378:731\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1714448.","journal-title":"N Engl J Med"},{"key":"1397_CR10","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","volume":"127","author":"O Neumann","year":"2022","unstructured":"Neumann O, Burn TC, Allg\u00e4uer M, et al. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. Br J Cancer. 2022;127:1540\u20139. https:\/\/doi.org\/10.1038\/s41416-022-01908-1.","journal-title":"Br J Cancer"},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","volume":"78","author":"G Kendre","year":"2023","unstructured":"Kendre G, Murugesan K, Brummer T, et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023;78:614\u201326. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.030.","journal-title":"J Hepatol"},{"key":"1397_CR12","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Krebshilfe D, AWMF). : S3-Leitlinie Diagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karzinome, Kurzversion 5.2, 2024, AWMF-Registernummer: 032-053OL https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/hcc-und-biliaere-karzinome\/; Zugriff am [21.09.2025]."},{"key":"1397_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427\u201334. https:\/\/doi.org\/10.1002\/hep.26890.","journal-title":"Hepatology"},{"key":"1397_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003\u201310. https:\/\/doi.org\/10.1038\/ng.3375.","journal-title":"Nat Genet"},{"key":"1397_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797\u2013805. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03028.x.","journal-title":"Histopathology"},{"key":"1397_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22:1290\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(21)00336-3.","journal-title":"Lancet Oncol"},{"key":"1397_CR17","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1200\/JCO.23.02010","volume":"42","author":"A Ohba","year":"2024","unstructured":"Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial. J Clin Oncol. 2024;42:3207\u201317. https:\/\/doi.org\/10.1200\/JCO.23.02010.","journal-title":"J Clin Oncol"},{"key":"1397_CR18","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1200\/JCO.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, Mizuno N, Sunakawa Y, et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J Clin Oncol. 2023;41:5569\u201378. https:\/\/doi.org\/10.1200\/JCO.23.00606.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1397_CR19","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh D, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the <Emphasis Type=\"SmallCaps\">KEYNOTE<\/Emphasis> \u2010158 and <Emphasis Type=\"SmallCaps\">KEYNOTE<\/Emphasis> \u2010028 studies. Int J Cancer. 2020;147(8):2190\u20138. https:\/\/doi.org\/10.1002\/ijc.33013.","journal-title":"Int J Cancer"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.519.","journal-title":"Ann Oncol"},{"key":"1397_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","volume":"22","author":"P Johannet","year":"2025","unstructured":"Johannet P, Rousseau B, Aghajanian C, et al. Therapeutic targeting of mismatch repair-deficient cancers. Nat Rev Clin Oncol. 2025;22:734\u201359. https:\/\/doi.org\/10.1038\/s41571-025-01054-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"1397_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","volume":"10","author":"A Vogel","year":"2025","unstructured":"Vogel A, Ducreux M. ESMO clinical practice guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10:104003. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104003.","journal-title":"ESMO Open"},{"key":"1397_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejca.2022.06.030","volume":"173","author":"LM Hondelink","year":"2022","unstructured":"Hondelink LM, Schrader AMR, Asri Aghmuni G, et al. The sensitivity of pan-TRK immunohistochemistry in solid tumours: a meta-analysis. Eur J Cancer. 2022;173:229\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.030.","journal-title":"Eur J Cancer"},{"key":"1397_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33:38\u201346. https:\/\/doi.org\/10.1038\/s41379-019-0324-7.","journal-title":"Mod Pathol"},{"key":"1397_CR25","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1200\/JCO.20.00762","volume":"38","author":"AKS Salama","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. JCO. 2020;38:3895\u2013904. https:\/\/doi.org\/10.1200\/JCO.20.00762.","journal-title":"JCO"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med"},{"key":"1397_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/cac2.70056","volume":"45","author":"J Li","year":"2025","unstructured":"Li J, Deng T, Gu Y, et al. Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: a pooled analysis of two phase I\/II trials. Cancer Commun. 2025;45:1500\u201312. https:\/\/doi.org\/10.1002\/cac2.70056.","journal-title":"Cancer Commun"},{"key":"1397_CR28","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;389:2125\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2308795.","journal-title":"N Engl J Med"},{"key":"1397_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2020;383:813\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2005653.","journal-title":"N Engl J Med"},{"key":"1397_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, Goto K, Kim D-W, et al. Efficacy of zenocutuzumab in NRG1 fusion\u2013positive cancer. N Engl J Med. 2025;392:566\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2405008.","journal-title":"N Engl J Med"},{"key":"1397_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2217\/fon-2023-0963","volume":"20","author":"C Yoo","year":"2024","unstructured":"Yoo C, Lamarca A, Choi HJ, et al. Brightline-2: a phase IIa\/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024;20:1069\u201377. https:\/\/doi.org\/10.2217\/fon-2023-0963.","journal-title":"Future Oncol"},{"key":"1397_CR32","doi-asserted-by":"publisher","unstructured":"Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"1397_CR33","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"key":"1397_CR34","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023\u201331. https:\/\/doi.org\/10.1038\/nbt.2696.","journal-title":"Nat Biotechnol"},{"key":"1397_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00428-016-2025-7","volume":"470","author":"ZC Deans","year":"2017","unstructured":"Deans ZC, Costa JL, Cree I, et al. Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Arch. 2017;470:5\u201320. https:\/\/doi.org\/10.1007\/s00428-016-2025-7.","journal-title":"Virchows Arch"},{"key":"1397_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","volume":"19","author":"LJ Jennings","year":"2017","unstructured":"Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of Next-Generation Sequencing-Based oncology panels: A joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017;19:341\u201365. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.01.011.","journal-title":"J Mol Diagn"},{"key":"1397_CR37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35:588\u2013606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005.","journal-title":"Ann Oncol"},{"key":"1397_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jmoldx.2021.12.012","volume":"24","author":"IM Silverman","year":"2022","unstructured":"Silverman IM, Li M, Murugesan K, et al. Validation and characterization of FGFR2 rearrangements in cholangiocarcinoma with comprehensive genomic profiling. J Mol Diagn. 2022;24:351\u201364. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.12.012.","journal-title":"J Mol Diagn"},{"key":"1397_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh M, Loriot Y, Brandi G, et al. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024;21:312\u201329. https:\/\/doi.org\/10.1038\/s41571-024-00869-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"1397_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4254\/wjh.v2.i12.419","volume":"2","author":"Y Nakanuma","year":"2010","unstructured":"Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2:419\u201327. https:\/\/doi.org\/10.4254\/wjh.v2.i12.419.","journal-title":"World J Hepatol"},{"key":"1397_CR41","unstructured":"Organisation mondiale de la sant\u00e9. Centre international de recherche Sur Le cancer. editors. Digestive system tumours. 5th ed. Lyon: International agency for research on cancer; 2019."},{"key":"1397_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1534005","volume":"15","author":"H Xu","year":"2025","unstructured":"Xu H, Liang Y, Tang W, et al. Clinical significance of HER2 overexpression in biliary tract carcinoma - a meta analysis. Front Oncol. 2025;15:1534005. https:\/\/doi.org\/10.3389\/fonc.2025.1534005.","journal-title":"Front Oncol"},{"key":"1397_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000533406","volume":"102","author":"C Vivaldi","year":"2024","unstructured":"Vivaldi C, Genovesi V, Ugolini C, et al. Mismatch repair deficiency in biliary tract cancer: prognostic implications and correlation with histology. Oncology. 2024;102:157\u201367. https:\/\/doi.org\/10.1159\/000533406.","journal-title":"Oncology"},{"key":"1397_CR44","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2025.43.16_suppl.4008","volume":"43","author":"TO Goetze","year":"2025","unstructured":"Goetze TO, Vogel A, Pratschke J, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: final results from the phase III AIO\/CALGP\/ACO-GAIN-Trial. JCO. 2025;43:4008\u20134008. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4008.","journal-title":"JCO"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01397-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:10:44Z","timestamp":1768446644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01397-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01397-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.B. has served on an advisory board for Taiho. M.Q. has received honoraria or served on advisory boards for Amgen, BMS, Celgene, Incyte, MSD, Merck, and Servier. B.B. has received honoraria from Roche, BMS, and AstraZeneca. A.M.S. has received honoraria from AstraZeneca, BMS, BeiGene, and MSD. E.P.D. declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15"}}